AbbVie (NYSE: ABBV) reported Q1 EPS of $3.16, $0.02 better than the analyst estimate of $3.14. Revenue for the quarter came in at $13.54 billion versus the consensus estimate of $13.63 billion.

GUIDANCE:

AbbVie sees FY2022 EPS of $13.92-$14.12, versus the consensus of $14.11.

• AbbVie is updating its adjusted diluted EPS guidance range for the full-year 2022 from $14.00 - $14.20 to $13.92 - $14.12 which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter 2022. The company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2022, as both cannot be reliably forecasted.

For earnings history and earnings-related data on AbbVie (ABBV) click here.